Benzinga · Feb 13, 2026
Curis To Resale From Time To Time Up To 107,706,700 Shares Of Common Stock By The Selling Stockholders
-SEC Filing
CR
NASDAQ · CRIS
Curis, Inc.
Healthcare · Biotechnology
$1.49
Down-$0.07 (-4.70%)
Updated Sep 1, 2026, 9:56 PM
SID Score
4.9/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 16.68M
- P/E ratio
- -0.55
- Dividend yield
- 0.00%
- 52-week range
- $0.18 – $11.40
- Volume
- 35.84K
- Avg. volume
- 86.2K
Price performance
CRIS price history
1M range · 21 trading sessions · Daily adjusted prices
CRIS closed at $1.49 after 21 trading sessions, down 71.07% for the selected period.
- Last close
- $1.49
- Period change
- -71.07%
- Period low
- $1.49
- Period high
- $5.15
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 31, 2026 | $1.48 | $1.53 | $1.4085 | $1.49 | 35.84K |
| Aug 28, 2026 | $1.51 | $1.58 | $1.45 | $1.49 | 119.83K |
| Aug 27, 2026 | $1.56 | $1.5892 | $1.40 | $1.50 | 288.29K |
| Aug 26, 2026 | $1.59 | $1.6099 | $1.51 | $1.54 | 105.41K |
| Aug 25, 2026 | $1.61 | $1.64 | $1.55 | $1.59 | 142.44K |
| Aug 24, 2026 | $1.60 | $1.65 | $1.5109 | $1.58 | 83.11K |
| Aug 21, 2026 | $1.63 | $1.6595 | $1.50 | $1.58 | 212.51K |
| Aug 20, 2026 | $1.71 | $1.715 | $1.59 | $1.61 | 133.88K |
| Aug 19, 2026 | $1.72 | $1.75 | $1.65 | $1.72 | 196.45K |
| Aug 18, 2026 | $1.83 | $1.93 | $1.68 | $1.70 | 282.12K |
| Aug 17, 2026 | $2.03 | $2.03 | $1.752 | $1.80 | 367.79K |
| Aug 14, 2026 | $1.83 | $2.08 | $1.74 | $1.80 | 470.55K |
| Aug 13, 2026 | $1.58 | $2.08 | $1.54 | $1.87 | 2.29M |
| Aug 12, 2026 | $2.33 | $2.40 | $1.63 | $1.67 | 1.15M |
| Aug 11, 2026 | $3.20 | $3.37 | $2.29 | $2.31 | 600.78K |
| Aug 10, 2026 | $4.07 | $4.15 | $3.5001 | $3.66 | 72.95K |
| Aug 7, 2026 | $4.35 | $4.35 | $3.955 | $4.02 | 70.02K |
| Aug 6, 2026 | $4.49 | $4.6999 | $4.02 | $4.41 | 78.96K |
| Aug 5, 2026 | $4.84 | $5.0633 | $4.39 | $4.545 | 54.59K |
| Aug 4, 2026 | $5.14 | $5.2799 | $4.6129 | $4.72 | 85.58K |
| Aug 3, 2026 | $5.13 | $5.50 | $5.06 | $5.15 | 84.51K |
Latest CRIS news
The latest Smart Investors Daily articles mentioning CRIS.
Stock researchCompany · Overview
CRIS research
Overview
Company profile and research snapshot.
Company profile
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 17, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 24, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 20, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 31, 2025 | HC Wainwright & Co. | Buy | — |
| Dec 10, 2024 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Feb 11, 2026
How The Narrative Around Curis (CRIS) Is Shifting As Assumptions Change Not The US$14 Target
Curis is back on investors’ radar after analysts reaffirmed a US$14.00 fair value per share, while quietly adjusting some of the key assumptions that sit behind that number. The discount rate shift to 11.03% and the steady revenue growth outlook of around 43.46% indicate that the story around risk and growth is being fine tuned rather than rewritten. As you read on, keep an eye on how these moving parts shape the evolving narrative around Curis and how you can stay on top of future...
Yahoo · Jan 11, 2026
Looking At The Narrative For Curis CRIS After Fresh Funding And Fair Value Reset
The latest update on Curis centers on a refreshed price target that holds fair value at US$14.00 while reshaping the story behind how that figure is reached. Analysts have adjusted the model inputs around revenue growth assumptions of 43.46% and a higher discount rate of 11.93%, reflecting a balance between confidence in longer term earnings power and caution on near term execution risk. As you read on, you will see how this evolving narrative is being built and how you can keep on top of...
Yahoo · Jan 9, 2026
Curis Announces Closing of Private Placement Totaling up to $80.8 Million in Gross Proceeds
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced the closing of its previously announced private placement (the "PIPE financing") for gross proceeds of up to $80.8 million to the Company, including initial gross proceeds to the Company of approximately $20.2 million, in each case before placement agent fees and offering expenses.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
